keyword
MENU ▼
Read by QxMD icon Read
search

GI NET

keyword
https://www.readbyqxmd.com/read/29861441/predictors-of-the-healthy-eating-index-and-glycemic-index-in-multi-ethnic-colorectal-cancer-families
#1
S Pamela K Shiao, James Grayson, Amanda Lie, Chong Ho Yu
For personalized nutrition in preparation for precision healthcare, we examined the predictors of healthy eating, using the healthy eating index (HEI) and glycemic index (GI), in family-based multi-ethnic colorectal cancer (CRC) families. A total of 106 participants, 53 CRC cases and 53 family members from multi-ethnic families participated in the study. Machine learning validation procedures, including the ensemble method and generalized regression prediction, Elastic Net with Akaike's Information Criterion with correction and Leave-One-Out cross validation methods, were applied to validate the results for enhanced prediction and reproducibility...
May 26, 2018: Nutrients
https://www.readbyqxmd.com/read/29794066/phase-ii-study-of-everolimus-and-octreotide-lar-in-patients-with-nonfunctioning-gastrointestinal-neuroendocrine-tumors-the-getne1003_everlar-study
#2
Jaume Capdevila, Alexandre Teulé, Jorge Barriuso, Daniel Castellano, Carlos Lopez, Jose Luis Manzano, Vicente Alonso, Rocío García-Carbonero, Emma Dotor, Ignacio Matos, Ana Custodio, Oriol Casanovas, Ramon Salazar
BACKGROUND: Antitumor activity of the combination of somatostatin analogues (SSAs) and the mammalian target of rapamycin (mTOR) inhibitor everolimus in patients with neuroendocrine tumors (NETs) has been reported but not confirmed in prospective trials. MATERIALS AND METHODS: This prospective, multicenter, single-arm phase II EVERLAR study evaluated everolimus 10 mg/day and the SSA octreotide 30 mg every 28 days in patients with advanced nonfunctioning well-differentiated gastrointestinal NETs (GI-NETs) that progressed in the last 12 months (ClinicalTrials...
May 23, 2018: Oncologist
https://www.readbyqxmd.com/read/29746336/resection-of-the-primary-gastrointestinal-neuroendocrine-tumor-improves-survival-with-or-without-liver-treatment
#3
Aaron Lewis, Mustafa Raoof, Philip H G Ituarte, John Williams, Laleh Melstrom, Daneng Li, Byrne Lee, Gagandeep Singh
OBJECTIVE: The aim of this study was to determine outcomes of primary tumor resection in metastatic neuroendocrine tumors across all primary tumor sites. BACKGROUND: Primary tumor resection (PTR) may offer a survival benefit in metastatic gastrointestinal neuroendocrine tumors (GI-NETs); however, few studies have examined the effect of primary site and grade on resection and survival. METHODS: This is a retrospective study of patients with metastatic GI-NETs at presentation between 2005 and 2011 using the California Cancer Registry (CCR) dataset merged with California Office of Statewide Health Planning and Development (OSHPD) inpatient longitudinal database...
May 9, 2018: Annals of Surgery
https://www.readbyqxmd.com/read/29741466/first-line-systemic-treatment-adherence-healthcare-resource-utilization-and-costs-in-patients-with-gastrointestinal-neuroendocrine-tumors-gi-nets-in-the-usa
#4
Michael S Broder, Beilei Cai, Eunice Chang, Tingjian Yan, Al B Benson
AIMS: To assess treatment adherence, healthcare resource utilization, and costs in GI NET patients initiating pharmacologic treatments in the US. METHODS: In 2 US commercial claims databases, patients ≥18 years with ≥1 inpatient or ≥2 outpatient GI NET claims within 12 months were identified. The first claim for pharmacologic treatments (e.g., somatostatin analogues [SSAs], cytotoxic chemotherapy [CC], targeted therapy [TT]) following diagnosis, between 7/1/2009-12/31/2014, was defined as the index date...
May 9, 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29733523/pattern-and-risk-factors-for-distant-metastases-in-gastrointestinal-neuroendocrine-neoplasms-a-population-based-study
#5
Wen Cai, Yinuo Tan, Weiting Ge, Kefeng Ding, Hanguang Hu
An increased incidence of gastrointestinal neuroendocrine neoplasms (GI-NENs) has been reported worldwide, and metastasis is the leading cause of GI-NEN-related death. Studies of different metastatic patterns in patients with different primary sites are limited. A population-based retrospective cohort study was conducted with the Surveillance, Epidemiology, and End Results (SEER) database. Patients with a GI-NEN diagnosis between 2010 and 2014 were included. All statistical analyses were performed using Intercooled Stata 12...
May 7, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29725436/a-small-well-differentiated-rectal-neuroendocrine-tumor-with-multiple-lymph-node-metastases-a-case-report
#6
Seung-Joo Nam, Gi Bong Chae, Seungkoo Lee, Sung Chul Park, Chang Don Kang, Sung Joon Lee
The incidence of rectal neuroendocrine tumor (NET), which is often diagnosed during routine surveillance endoscopy, is increasing. The majority of these tumors are small and asymptomatic, possessing benign features with favorable prognoses. At present, small rectal NETs without high-risk factors are typically treated by local resection, including endoscopic mucosal resection, endoscopic submucosal dissection, or transanal endoscopic microsurgery, with or without additional imaging follow-up by abdominal computed tomography or magnetic resonance imaging...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29713473/nkx2-2-pdx-1-and-cdx-2-as-potential-biomarkers-to-differentiate-well-differentiated-neuroendocrine-tumors
#7
Michelle X Yang, Ryan F Coates, Abiy Ambaye, Valerie Cortright, Jeannette M Mitchell, Alexa M Buskey, Richard Zubarik, James G Liu, Steven Ades, Maura M Barry
Background: Well-differentiated neuroendocrine tumors (NET) most frequently arise from the gastrointestinal tract (GI), pancreas, and lung. Patients often present as metastasis with an unknown primary, and the clinical management and outcome depend on multiple factors, including the accurate diagnosis with the tumor primary site. Determining the site of the NET with unknown primary remains challenging. Many biomarkers have been investigated in primary NETs and metastatic NETs, with heterogeneous sensitivity and specificity observed...
2018: Biomarker Research
https://www.readbyqxmd.com/read/29662560/impact-of-68-ga-dota-peptide-pet-ct-on-the-management-of-gastrointestinal-neuroendocrine-tumour-gi-net-malaysian-national-referral-centre-experience
#8
Teik Hin Tan, Ching Yeen Boey, Boon Nang Lee
Purpose: The National Cancer Institute is the only referral centre in Malaysia that provides 68 Ga-DOTA-peptide imaging. The purpose of this study is to determine the impact of 68 Ga-DOTA-peptide PET/CT on the management of gastrointestinal neuroendocrine tumours (GI-NET). Materials and Methods: A cross-sectional study was performed to review the impact of 68 Ga-DOTA-peptide (68 Ga-DOTATATE or 68 Ga-DOTATOC) PET/CT on patients with biopsy-proven GI-NET between January 2011 and December 2015...
April 2018: Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29562673/a-meta-regression-analysis-of-the-effectiveness-of-mosquito-nets-for-malaria-control-the-value-of-long-lasting-insecticide-nets
#9
Gi-Geun Yang, Dohyeong Kim, Anh Pham, Christopher John Paul
Long-lasting insecticidal nets (LLINs) have been widely used as an effective alternative to conventional insecticide-treated nets (ITNs) for over a decade. Due to the growing number of field trials and interventions reporting the effectiveness of LLINs in controlling malaria, there is a need to systematically review the literature on LLINs and ITNs to examine the relative effectiveness and characteristics of both insecticide nettings. A systematic review of over 2000 scholarly articles published since the year 2000 was conducted...
March 19, 2018: International Journal of Environmental Research and Public Health
https://www.readbyqxmd.com/read/29507481/cost-effectiveness-of-everolimus-for-the-treatment-of-advanced-neuroendocrine-tumours-of-gastrointestinal-or-lung-origin-in-canada
#10
A Chua, A Perrin, J F Ricci, M P Neary, M Thabane
Background: In 2016, everolimus was approved by Health Canada for the treatment of unresectable, locally advanced or metastatic, well-differentiated, non-functional, neuroendocrine tumours (NET) of gastrointestinal (GI) or lung origin in adult patients with progressive disease. This analysis evaluated the cost-effectiveness of everolimus in this setting from a Canadian societal perspective. Methods: A partitioned survival model was developed to compare the cost per life-year (LY) gained and cost per quality-adjusted life-year (QALY) gained of everolimus plus best supportive care (BSC) versus BSC alone in patients with advanced or metastatic NET of GI or lung origin...
February 2018: Current Oncology
https://www.readbyqxmd.com/read/29434915/immunohistochemical-cd73-expression-status-in-gastrointestinal-neuroendocrine-neoplasms-a-retrospective-study-of-136-patients
#11
Kohei Ono, Eisuke Shiozawa, Nobuyuki Ohike, Tomonori Fujii, Hideki Shibata, Tetsuya Kitajima, Koichiro Fujimasa, Naoko Okamoto, Yukiko Kawaguchi, Tasuku Nagumo, Sakiko Tazawa, Mayumi Homma, Toshiko Yamochi-Onizuka, Tomoko Norose, Hitoshi Yoshida, Masahiko Murakami, Gensyu Tate, Masafumi Takimoto
The WHO 2010 classification divides gastrointestinal neuroendocrine neoplasms (GI-NENs) into neuroendocrine tumor (NET) G1, NET G2, neuroendocrine carcinoma (NEC) and mixed adenoendocrine carcinoma (MANEC) groups. A total of 136 cases of GI-NENs diagnosed at our hospitals as gastrointestinal carcinoids, endocrine cell carcinomas and NENs over the last 11 years, using the WHO 2010 classification were assessed. Among the 136 cases, 88.2% (120/136) were classified into the NET group (NET G1/G2) and 11.8% (16/136) were classified into the NEC group (NEC/MANEC)...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29374260/configurable-topological-textures-in-strain-graded-ferroelectric-nanoplates
#12
Kwang-Eun Kim, Seuri Jeong, Kanghyun Chu, Jin Hong Lee, Gi-Yeop Kim, Fei Xue, Tae Yeong Koo, Long-Qing Chen, Si-Young Choi, Ramamoorthy Ramesh, Chan-Ho Yang
Topological defects in matter behave collectively to form highly non-trivial structures called topological textures that are characterised by conserved quantities such as the winding number. Here we show that an epitaxial ferroelectric square nanoplate of bismuth ferrite subjected to a large strain gradient (as much as 105  m-1 ) associated with misfit strain relaxation enables five discrete levels for the ferroelectric topological invariant of the entire system because of its peculiar radial quadrant domain texture and its inherent domain wall chirality...
January 26, 2018: Nature Communications
https://www.readbyqxmd.com/read/29357436/mechanism-for-higher-urine-ph-in-normal-women-compared-with-men
#13
Elaine M Worcester, Kristin J Bergsland, Daniel L Gillen, Fredric L Coe
Regulation of acid-base metabolism maintains the pH of body fluids within a tight range. Urine pH (UpH) is also regulated under normal conditions. Median pH of 24-h urines is ~6, but others have noted that UpH in women is higher than men, which has been attributed to differences in diet. If true, it would help to explain the fact that calcium phosphate stones, which form at higher urine pH, are much more common in women than in men. We studied 14 normal subjects (7 men and 7 women) fed identical meals in a Clinical Research Center...
April 1, 2018: American Journal of Physiology. Renal Physiology
https://www.readbyqxmd.com/read/29261249/real-world-economic-value-of-a-21-gene-assay-in-early-stage-breast-cancer
#14
Stanley E Waintraub, Donna McNamara, Deena Mary Atieh Graham, Andrew L Pecora, John Min, Tommy Wu, Hyun Gi Noh, Jacqueline Connors, Ruth Pe Benito, Kelly Choi, Eric Schultz, Stuart L Goldberg
OBJECTIVES: Value-based payment reforms shift cost-containment responsibilities to the physician. Although gene expression profiling (GEP) utilizing a 21-gene panel among patients with early-stage, axillary lymph node-negative, hormone receptor-positive, HER2/neu oncogene-negative breast cancer is able to identify a cohort that may achieve excellent outcomes without adjuvant chemotherapy, high up-front costs (list price, $4175) could dissuade usage. STUDY DESIGN: Retrospective review of consecutive patients with breast cancer treated at a single cancer center...
December 1, 2017: American Journal of Managed Care
https://www.readbyqxmd.com/read/29213282/determination-of-mammalian-target-of-rapamycin-hyperactivation-as-prognostic-factor-in-well-differentiated-neuroendocrine-tumors
#15
G Lamberti, C Ceccarelli, N Brighi, I Maggio, D Santini, C Mosconi, C Ricci, G Biasco, D Campana
Purpose: To evaluate the role of the activation of mTOR (phosphorylated mTOR, p-mTOR) and the expression SSTR2A and IGF-1R as prognostic factor in well-differentiated neuroendocrine tumors. Methods: A retrospective study was conducted on data from patients with diagnosis of neuroendocrine tumor originated from pancreas (pNET) or gastrointestinal tract (stomach, appendix, and ileus; GI-NET) made between January 2003 and December 2004 and followed up at our institution...
2017: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/29194046/updates-on-the-biology-of-serotonin-and-tryptophan-hydroxylase
#16
Tara Swami, H Christian Weber
PURPOSE OF REVIEW: To summarize the most recent findings relevant to the biology of serotonin (5-hydroxytryptamine; 5-HT) and the enzyme tryptophan hydroxylase (TPH) in human gastrointestinal disease. RECENT FINDINGS: Serotonin is synthesized in the central nervous system (CNS) and the gastrointestinal tract where it is secreted from enteroendocrine cells. Its biosynthesis is regulated by two isoforms of the enzyme TPH of which TPH1 is localized predominantly in gastrointestinal enteroendocrine cells...
February 2018: Current Opinion in Endocrinology, Diabetes, and Obesity
https://www.readbyqxmd.com/read/29142475/predictive-factors-associated-with-carcinoid-syndrome-in-patients-with-gastrointestinal-neuroendocrine-tumors
#17
Beilei Cai, Michael S Broder, Eunice Chang, Tingjian Yan, David C Metz
AIM: To discover unknown factors associated with carcinoid syndrome (CS) with the goal of earlier diagnosis of CS. METHODS: In this retrospective case-control study using United States administrative claims, patients (≥ 18 years) newly-diagnosed with gastrointestinal neuroendocrine tumors (GI NETs) without CS (controls) were exactly matched to patients with CS (cases) based on NET diagnosis date at a 3-to-1 ratio. Study index date was first CS diagnosis (controls: same distance from NET diagnosis as cases)...
October 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29081664/impact-of-prior-therapies-on-everolimus-activity-an-exploratory-analysis-of-radiant-4
#18
Roberto Buzzoni, Carlo Carnaghi, Jonathan Strosberg, Nicola Fazio, Simron Singh, Fabian Herbst, Antonia Ridolfi, Marianne E Pavel, Edward M Wolin, Juan W Valle, Do-Youn Oh, James C Yao, Rodney Pommier
BACKGROUND: Recently, everolimus was shown to improve median progression-free survival (PFS) by 7.1 months in patients with advanced, progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) tract compared with placebo (HR, 0.48; 95% CI, 0.35-0.67; P <0.00001) in the Phase III, RADIANT-4 study. This post hoc analysis evaluates the impact of prior therapies (somatostatin analogs [SSA], chemotherapy, and radiotherapy) on everolimus activity...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29072093/the-utility-of-68-ga-dotatate-positron-emission-tomography-computed-tomography-in-the-diagnosis-management-follow-up-and-prognosis-of-neuroendocrine-tumors
#19
Amit Tirosh, Electron Kebebew
Neuroendocrine tumors (NETs) are rare neoplasms that emerge mainly from the GI tract, pancreas and respiratory tract. The incidence of NETs has increased more than sixfold in the last decades. NETs typically express somatostatin receptors on their cell surface, which can be targeted by 'cold' somatostatin analogs for therapy or by 'hot' radiolabeled somatostatin analogs for tumor localization and treatment. 68-Gallium-DOTA peptides (DOTATATE, DOTATOC, DOTANOC) positron emission tomography/computed tomography is a highly accurate imaging modality for NETs that has been found to be more sensitive for NET detection than other imaging modalities...
January 2018: Future Oncology
https://www.readbyqxmd.com/read/28970728/real-world-treatment-patterns-of-gastrointestinal-neuroendocrine-tumors-a-claims-database-analysis
#20
Al B Benson, Michael S Broder, Beilei Cai, Eunice Chang, Maureen P Neary, Elya Papoyan
AIM: To describe real-world treatment patterns of gastrointestinal neuroendocrine tumors (GI NET). METHODS: In this retrospective cohort study, we used 2009-2014 data from 2 United States commercial claims databases to examine newly pharmacologically treated patients using tabular and graphical techniques. Treatments included somatostatin analogues (SSA), cytotoxic chemotherapy (CC), targeted therapy (TT), interferon (IF) and combinations. We identified patients at least 18 years of age, with ≥ 1 inpatient or ≥ 2 outpatient claims for GI NET who initiated pharmacologic treatment from 7/1/09-6/30/14...
September 7, 2017: World Journal of Gastroenterology: WJG
keyword
keyword
116027
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"